Lilly says Phase 3b TOGETHER-PsO data show broader biomarker shifts with Taltz plus Zepbound vs Taltz alone

• Eli Lilly disclosed new exploratory biomarker findings from its Phase 3b TOGETHER-PsO trial at Fall Clinical 2026.
• Combined Taltz with Zepbound treatment showed broader biological changes than Taltz alone, starting early in treatment.
• The biomarker shifts aligned with improved skin clearance alongside meaningful weight loss, reinforcing a dual-disease treatment strategy.
• Results build on previously presented clinical outcomes from the same study through its primary assessment, with longer-term effects tracked to Week 52.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090645PR_NEWS_USPR_____DE67439) on October 09, 2026, and is solely responsible for the information contained therein.